**Supplemental material**

**Supplemental Table 1. Causes of death**

|  |  |
| --- | --- |
| ***Immediate treatment arm*** | ***Time to event (years)*** |
| Haemorrhage intracranial  |  | 1.48 |
| Squamous cell carcinoma of lung  |  | 1.57 |
| Thermal burn  |  | 0.71 |
| Homicide  |  | 0.16 |
| Stab wound  |  | 1.41 |
| ***Deferred treatment arm*** |  |
| Drowning  |  | 1.66 |
| Acute kidney injury  |  | 1.49 |
| Burkitt's lymphoma  |  | 2.11 |

**Supplemental Table 2a. Biomarkers at enrollment, and changes to month 8, all patients with HIV RNA** <**3,000 copies/mL at baseline.**

Treatment N Median (IQR) enrollment Median change (IQR) to month 8

***D-dimer (microg/mL)***

Immediate 452 0.331 (0.227, 0.507) -0.017 (-0.114, 0.071)

Deferred 480 0.313 (0.221, 0.503) 0.009 (-0.063, 0.092)

 *Median difference at 8 months* ***-0.032 (-0.052 to -0.012) p=0.002***

***CRP (microg/mL)***

Immediate 454 1.70 (0.68, 4.43) 0.18 (-0.44, 2.21)

Deferred 487 1.46 (0.59, 3.71) 0.02 (-0.76, 1.00)

 *Median difference at 8 months* ***0.35 (0.11 to 0.62) p=0.002***

***Serum amyloid A (mg/L)***

Immediate 454 4.74 (2.40, 9.16) -0.173 (-2.135, 1.738)

Deferred 487 4.08 (2.24, 7.72) 0.040 (-1.742,1.778)

 *Median difference at 8 months* ***-0.25 (-0.69 to 0.19) p=0.252***

***sICAM-1 (microg/mL)***

Immediate 454 507.8 (386.4, 646.8) -15.4 (-109.2, 61.0)

Deferred 487 493.9 (388.8, 660.2) -2.1 (-76.1, 73.6)

 *Median difference at 8 months* ***-15.3 (-32.0 to 1.6) p=0.075***

***sVCAM-1 (microg/mL)***

Immediate 454 606.8 (473.3, 792.6) -71.5 (-162.5, 22.4)

Deferred 487 628.0 (477.1, 785.5) -3.1 (-88.3, 88.7)

 *Median difference at 8 months* ***-72.7 (-92.2 to -53.0) p<0.001***

***IL6 (pg/mL)***

Immediate 453 1.357 (0.900, 2.090) -0.059 (-0.454, 0.425)

Deferred 486 1.276 (0.916, 2.007) -0.047 (-0.421, 0.319)

 *Median difference at 8 months*  ***0.009 (-0.087 to 0.108) p=0.856***

***IL27 (pg/mL)***

Immediate 455 227.0 (119.2, 492.6) -4.6 (-83.3, 83.1)

Deferred 488 220.9( 107.8, 473.2) 1.6 (-74.0,77.5)

 *Median difference at 8 months* ***-3.2 (-21.2 to 15.1) p=0.723***

Notes: Patients included if they had a measurement at baseline and month 8. Values are changes from baseline. Values below lower or upper limits of detection are included as those limits.

**Supplemental Table 2b. Biomarkers at enrollment, and changes to month 8, all patients with HIV RNA** ≤**50 copies/mL at baseline.**

Treatment N Median (IQR) at enrolment Median change (IQR) to month 8

***D-dimer (microg/mL)***

Immediate 34 0.321 (0.234, 0.459) -0.018 (-0.070, 0.122)

Deferred 39 0.319 (0.215, 0.534) 0.008 (-0.058, 0.107)

  *Median difference at 8 months* ***-0.017 (-0.086 to 0.057) p=0.646***

***CRP (microg/mL)***

Immediate 34 2.50 (0.88, 7.39) 0.07 (-0.40, 0.97)

Deferred 43 1.41 (0.60, 3.62) -0.01 (-0.80, 1.09)

  *Median difference at 8 months* ***0.12 (-0.58 to 0.93) p=0.682***

***Serum amyloid A (mg/L)***

Immediate 34 4.72 (2.13, 11.85) -0.69 (-3.34, 1.09)

Deferred 43 3.72 (1.95, 6.94) -0.31 (-1.09, 0.58)

  *Median difference at 8 months* ***-0.67 (-2.26 to 0.73) p=0.305***

***sICAM-1 (microg/mL)***

Immediate 34 483.2 (367.5, 616.0) 13.4 (-64.4, 139.5)

Deferred 43 477.5 (391.8, 571.6) -6.8 (-105.6, 66.0)

  *Median difference at 8 months 49.3* ***(-16.4 to 128.4) p=0.132***

***sVCAM-1 (microg/mL)***

Immediate 34 550.8 (425.6, 702.7) 34.1 (-75.4, 156.2)

Deferred 43 611.2 (415.8, 806.1) -36.6 (-102.7, 37.9)

  *Median difference at 8 months* ***83.2 (-3.1 to 169.0) p=0.050***

***IL6 (pg/mL)***

Immediate 34 1.32 ( 0.99, 2.57) -0.02 (-0.39, 0.33)

Deferred 43 1.17 (0.89, 1.51) -0.08 (-0.36, 0.26)

  *Median difference at 8 months* ***0.01 (-0.29 to 0.26) p=0.959***

***IL27 (pg/mL)***

Immediate 34 183.4 (86.0, 491.2) 18.9 (-49.3, 121.7)

Deferred 43 190.4 (117.9, 376.4) 4.3 (-42.2, 117.8)

  *Median difference at 8 months* ***12.0 (-47.8 to 77.1) p=0.678***

Notes: Patients included if they have a measurement at baseline and month 8. Values at month 8 are changes from baseline. Values below lower or upper limits of detection are included as those limits.